Skip to content

Palvella Therapeutics, Inc.: 10-Q filed 2014-06-02

What Palvella Therapeutics, Inc. reported in its quarterly report filed 2014-06-02 (fiscal Q3 2014): 19 published measures, 46 facts as tagged in accession 0001583648-14-000007.

This filing

Form
10-Q (quarterly report)
Filed
2014-06-02
Fiscal period
fiscal Q3 2014
Accession
0001583648-14-000007 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Palvella Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-31196USD
At 2013-06-305,200USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-314,974USD
At 2013-06-30474USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-03-31196USD
At 2013-12-3190USD
At 2013-06-305,200USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-1,544USD90
2013-07-01 to 2014-03-31-9,504USD274
2013-05-24 to 2014-03-31-9,504USD312

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-294USD90
2013-07-01 to 2014-03-31-7,004USD274
2013-05-24 to 2014-03-31-7,004USD312

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
2013-07-01 to 2014-03-310USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
2013-07-01 to 2014-03-310USD274
2013-05-24 to 2014-03-310USD312

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-01-01 to 2014-03-31400USD90
2013-07-01 to 2014-03-312,000USD274
2013-05-24 to 2014-03-317,200USD312

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-03-31-9,778USD
At 2013-06-30-274USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-01-01 to 2014-03-315,000,000shares90
2013-07-01 to 2014-03-315,000,000shares274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-1,544USD90
2013-07-01 to 2014-03-31-9,504USD274
2013-05-24 to 2014-03-31-9,504USD312

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,544USD90
2013-07-01 to 2014-03-319,504USD274
2013-05-24 to 2014-03-319,504USD312

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-315,000,000shares
At 2013-06-305,000,000shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2014-03-31-4,778USD
At 2013-06-304,726USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-312,500USD
At 2013-06-300USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-1,544USD90
2013-07-01 to 2014-03-31-9,504USD274
2013-05-24 to 2014-03-31-9,504USD312

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-3118USD90
2013-07-01 to 2014-03-3166USD274
2013-05-24 to 2014-03-3166USD312

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
2013-07-01 to 2014-03-310USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-05-24 to 2014-03-315,000USD312

Inspect the source

Entity
Palvella Therapeutics, Inc. / CIK 0001583648
Captured
2026-09-20T09:22:58.497Z
SEC response SHA-256
6b68c40c9037b15f9345bb6bb1fdc7777b1252c77cab2e34faa81275beefef40

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583648.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))